Hi Gary, regarding the updating of the clinical trials

New Post Public Reply Private Reply Replies (1) Message Board
BruceLake GaryM #10692
501
Hi Gary, regarding the updating of the clinical trials database.

https://clinicaltrials.gov/ct2/show/results/NCT02976779

I first contacted management back in March with regards to the above site and why it still states that: "The study is not open yet for participant recruitment". After several unsatisfactory attempts at getting a reasonable answer I finally received an email from Alon Sinai on May 11. To summarize he essentially stated that:
1. All volunteers were already chosen.
2. Most biotech companies report only final results , some report midterm, and for obvious reasons they do the same.
3. Most studies at the safety stage are framed to take a year.

Back in May I shared the email by PM with a few people but was reluctant to post it publicly. My reluctance stems from the fact that there are too many people here that either don't want the company to succeed or they misinterpret everything they read and distort it to suit their purposes, whatever they may be.

As for me, I don't need a blow-by-blow description on how the study is going and what they are having for breakfast. I'm happy with the answer I got to that one question, and I'm prepared to wait for as long as it takes.

Thanks

Here is the May 11 email response from Alon Sinai.

Dear xxxxx and Hello everyone

First , thank you for contacting us .

I will try and stay as short and to the point as possible.

General:

OWC pharmaceutical research is a biotech company and not a toy manufacturer in an automated China production line .

I am sure you realize that R&D and exploring new inventions is unknown road . It's a road we have to build .

Luckily for you as a shareholder and us as a company our pre-clinical phase for the cream's efficacy study led to findings that ( being very careful) are unique , with no previous records of any scientific findings , even remotely close to what we found ! Up to 70% reduction of biological markers directly related to psoriasis.

FYI , pre-clinical = on human tissues but not on human beings .

I am also aware of many "web-speculations" on timing and scientific course . None of them is supported by any of the official company's filings or communications!

Last , as a prolog to my answers to your inquiry let me add :

I am not sure if you are aware at what conducting a safety clinical study ( similar to FDA phase I) so let me give you some highlights :

1. The tested people have to be 100% healthy and none biased .

2. They have to be picked Randomly ( responding to Adds) and prove that they are not associated with the company or its competitors.

3. After the first screening they have to go through physical and mental check up ( for instance , once we checked some of the volunteers we happily advised 2 women that they are pregnant)

4. Than all volunteers are invited to the hospital to try and determine , for each of them , dates and timing for attending the hospital. During the study some are always asking to re-schedule , due to personal issues .

There are many other items and pieces that has to fall in place to finish building the puzzle . That is why with most studies the safety stage is framed to take a year

your inquiries below :

1. NIH reporting system is not a "FedEx" tracking system . Most biotech companies report only final results , some report midterm. All for purpose of protecting IP and disclose as less as possible to their competitors. So do we

2. You cannot chose to volunteer from the follow reasons :

* all volunteers were chosen already

* in order to volunteer at the beginning, you had to reside in Israel and able to arrive at the hospital, twice a week for 3 months

Last

Our main focus right now Is :

* complete including our pre-clinical findings into our IP so it will be stronger and un breakable. ( we announced)

* follow up to the vested interest we generated with international organizations ( commercial and scientific) after we announced the pre clinical findings

* continue the preparations to get our product to the market

So forgive me , in advance , if I don't answer fast enough

Thanks

Alon

Alon Sinai, COO

One World Cannabis Ltd. (OWC)

22, Shacham Street (Beit Dvir, 2nd floor), Petach Tikva, Israel

Mailing Address: PO Box 8324, Petach Tikva, 4918103, Israel

Tel: + 972 (0)3 7582659; + 972 (0)52 4029178

Email: alon.sinai@OWCpharma.com

www.OWCpharma.com

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Liberty Hill: 50 Years of Grassroots Revolution

Updated Category News Views 4

Half a Century of Community Empowerment You don't see organizations sticking to their guns for fifty years without having something real to offer. Liberty Hill Foundation is celebrating this colossal milestone in style by throwing their weight behind 17 grassroots groups under the 2026 Fund for Change. They're not just tossing money around but are genuinely becoming the...

Continue Reading
Moore Law Investigates Aardvark Therapeutics' Risks

Updated Category News Views 2

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...

Continue Reading
Unpacking RAGEism: Power Dynamics in U.S. Policies

Updated Category News Views 3

Seeing Patterns in Crisis: Jackson and Flint When Jackson, Mississippi's latest water crisis hit the news, it wasn't the first time folks were left high and dry. No, this fiasco's got deep roots, and it resonates with another infamous case: Flint, Michigan. In Maya Rockeymoore Cummings' book, RAGEism, these are badge-worthy examples of 'Resource Hoarding' where government...

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 2

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
Atli Launches: AI-Powered eSIM Revolutionizes Travel

Updated Category News Views 5

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

Continue Reading
RTI's $14M Boost: A Game-Changer for Tech Innovators

Updated Category News Views 6

Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...

Continue Reading
BusyBee AI Revolutionizes Classroom Feedback Efficiency

Updated Category News Views 2

Grading Overhaul: BusyBee's Role in Education Here's a twist for the history books: Agilix Labs' BusyBee, a slick AI assistant built right into the Buzz platform on Amazon Bedrock, is kicking traditional grading methods to the curb. This little helper is grading close to a million K-12 student submissions every month, meticulously approved by real teachers. Quite the...

Continue Reading
Bitwise Pulls Plug on Dogecoin ETF Amid Market Risks

Updated Category News Views 6

Bitwise Ditches Dogecoin ETF: End of a Speculative Era Who knew that a digital asset inspired by an internet meme would get a platform on Wall Street? Well, Bitwise did. They rallied behind Dogecoin, launching the Bitwise Dogecoin ETF, ticker BWOW. But as of September 10, 2026, the fund's journey is coming to an end with liquidation just around the corner. What Sparked...

Continue Reading
RealNex Navigator Upgrades Unveil Vast CRE Capabilities

Updated Category News Views 5

The Dawn of a New Navigator for CRE RealNex is unleashing a storm of enhancements to its Navigator platform, shaking up the commercial real estate (CRE) scene. Their latest upgrades are setting a new precedent for how brokers use technology to sharpen their game, handle transactions, and strategize in a market that never sleeps. Diving Deep into the Latest Upgrades First...

Continue Reading
CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Updated Category News Views 13

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

Continue Reading

Top 5 Most Recently Viewed Articles

UBS Enhances Azelis Rating to 'Buy' on Strong Recovery Outlook

Updated Category News Views 192

UBS Upgrades Azelis to 'Buy' Based on Positive Market Signals In a significant move for investors, UBS Global Research has upgraded Azelis Group (EBR: AZE) from a "neutral" stance to a "buy" rating. This transition comes as analysts recognize the recovery potential and favorable valuation of the Belgium-based company. Positive Market Response Following the announcement...

Continue Reading
Algae-C Inc. Merges with Rockcliffe Labs for Enhanced Biotech Growth

Updated Category News Views 192

Algae-C Inc. Merges with Rockcliffe Labs for Enhanced Biotech Growth Algae-C Inc. is now officially part of Rockcliffe Labs, a Canadian late-stage biotech innovation platform. This strategic acquisition allows Algae-C to enhance its operational capabilities and leverage Rockcliffe Labs' extensive resources and expertise in the biotechnology sector. Transaction Overview...

Continue Reading
Crown Crafts, Inc. to Discuss Q2 Fiscal 2026 Earnings Soon

Updated Category News Views 126

Crown Crafts, Inc. to Announce Q2 Fiscal 2026 Results Crown Crafts, Inc. (NASDAQ: CRWS) has made an important announcement regarding its upcoming financial results. The company plans to share its operational performance for the second quarter of fiscal year 2026 before market openings on a specified date in November 2025. This event underscores Crown Crafts’ commitment...

Continue Reading
AFGB Stock Hits 52-Week Low, Analyzing Market Trends

Updated Category News Views 256

AFGB Stock Experiences 52-Week Low Amid Market Trends American Financial Group (NYSE: AFG) has recently seen its stock, PR B (AFGB), hit a concerning 52-week low, reaching $22.7. This notable decline comes as investors contend with a fluctuating market environment that has created uncertainty among many stocks. At a market capitalization of $11.5 billion, the company's...

Continue Reading
KBR Secures $113 Million Air Force Contract for Innovation

Updated Category News Views 63

KBR Secures $113 Million Air Force Contract for Innovation KBR, Inc. (NYSE: KBR) has officially announced that it’s landed a five-year contract worth $113 million. This important contract focuses on aeronautical systems research for the Air Force Life Cycle Management Center Mobility Directorate. Purpose of the Contract Awarded under the Department of Defense...

Continue Reading